NextPlat (NXPL) Equity Income (2022 - 2023)

NextPlat's (NXPL) quarterly Equity Income came in at -$1.4 million in Q2 2023, down 4296.88% quarter-over-quarter from -$32000.0 in Q1 2023.

Analysis

NextPlat (NXPL) Equity Income (2022 - 2023) Analysis & Trends

NextPlat (NXPL) has reported Equity Income for 2 consecutive years, with -$1.4 million the latest figure, recorded in Q2 2023.

On a quarterly basis, Equity Income changed N/A year-over-year to -$1.4 million in Q2 2023; TTM through Mar 2024 was -$1.4 million, a 20.55% increase from a year earlier, with the FY2023 full-year figure at -$1.4 million, up 17.19% from the prior year.
Equity Income was -$1.4 million for Q2 2023 at NextPlat, down from -$32000.0 in the prior quarter.
Over five years, Equity Income peaked at $1.7 million in Q4 2022 and troughed at -$3.5 million in Q3 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Teva Pharmaceutical Industries	42.34 Bn	38.68 Bn	2.15 Bn	-500,000.00
2	Viatris	19.39 Bn	18.50 Bn	1.46 Bn	-
3	Dr Reddys Laboratories	9.99 Bn	9.85 Bn	396.53 Mn	-84,502.07
4	Amneal Pharmaceuticals	5.57 Bn	5.53 Bn	334.51 Mn	-
5	Bausch Health Companies	2.45 Bn	1.58 Bn	2.10 Bn	-
6	Ani Pharmaceuticals	1.70 Bn	1.34 Bn	165.89 Mn	-
7	Alvotech	1.66 Bn	1.52 Bn	2.56 Mn	-
8	Amphastar Pharmaceuticals	985.90 Mn	695.77 Mn	93.47 Mn	-
9	Fennec Pharmaceuticals	434.07 Mn	392.82 Mn	17.15 Mn	-
10	NextPlat	24.77 Mn	12.93 Mn	4.69 Mn	-

Historic Data

Download Data